ERBB2 and breast carcinoma: A German trial, the PLAN B study, compared 6 cycles of TC with 4 cycles of anthracyclines followed in sequence by 4 cycles of docetaxel as adjuvant therapy for patients with HER2-negative breast cancer tumors.